Bluebird Bio (BLUE) Posts Q1 Loss of 44c/Share

Bluebird Bio (NASDAQ: BLUE) reported Q1 EPS of ($0.44), $0.12 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.23 million.

For earnings history and earnings-related data on Bluebird Bio (BLUE) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
• Keurig Dr Pepper upgraded at Barclays as breakup plan gains clarity